Welcome to our dedicated page for NYSE news (Ticker: nyse), a resource for investors and traders seeking the latest updates and insights on NYSE stock.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is a clinical-stage biopharmaceutical company pioneering targeted radiotherapies for patients with advanced cancers. This news hub provides investors and healthcare professionals with timely updates on the company’s clinical developments, regulatory milestones, and strategic partnerships.
Access authoritative information about Actinium’s Antibody Radiation Conjugate (ARC) platform, including progress on lead candidates Iomab-B for bone marrow transplant conditioning and Iomab-ACT for CAR-T therapy preparation. Our curated news collection features press releases on trial results, FDA communications, and collaborations with leading cancer research centers.
Key updates include phase 3 trial data for hematologic malignancies, manufacturing advancements for radiotherapy agents, and scientific presentations at major oncology conferences. All content is vetted for accuracy and relevance to treatment innovation in cellular therapies.
Bookmark this page for streamlined tracking of Actinium’s progress in redefining cancer treatment paradigms through precision radiotherapy. Verify time-sensitive updates directly through SEC filings and official company communications.
Actinium Pharmaceuticals (NYSE: ATNM) presented preclinical data for ATNM-400, an Actinium-225 antibody radioconjugate, at SABCS 2025 showing potent anti-tumor activity across HR+, TNBC, and tamoxifen- and trastuzumab-resistant breast cancer models.
Key findings include significant tumor-growth inhibition in HR+ and TNBC models, increased target expression and enhanced cytotoxicity in treatment-resistant models, combination-induced tumor regression in a trastuzumab-resistant model, sustained tumor uptake through 144 hours, and rapid clearance from normal organs suggesting a differentiated tolerability profile.
Lockheed Martin (NYSE:LMT) is nearing completion of a new 88,000-square-foot Missile Assembly Building-5 (MAB-5) in Courtland, Alabama, with on-track completion by early 2026 and a formal grand opening to follow.
MAB-5 is purpose-built to produce the Next Generation Interceptor (NGI) for the Missile Defense Agency, emphasizing speed, producibility and repeatability using digital engineering tools including digital twins, model-based systems engineering and virtual testing. The Courtland site employs nearly 500 people, with about 100 employees projected for MAB-5 when fully operational; adjacent Troy facilities will support integration and large-scale manufacturing.
Alexander & Baldwin (NYSE: ALEX) agreed to be taken private in a definitive merger for $21.20 per share cash, implying an enterprise value of approximately $2.3 billion including outstanding debt. The price represents a 40.0% premium to the December 8, 2025 closing price. The transaction, unanimously approved by the board, is expected to close in Q1 2026 subject to customary conditions and shareholder approval. A fourth-quarter 2025 dividend of $0.35 per share was declared, payable January 8, 2026; the merger consideration will be reduced to reflect this dividend. The Investor Group plans to keep A&B's Honolulu headquarters, retain local leadership, and invest over $100 million across the portfolio.
Adient (NYSE:ADNT) completed acquisition of a 49% equity stake in SCI (Zhangjiakou) Co., Ltd. and formed a strategic joint venture on Dec. 8, 2025.
The JV will develop and manufacture automotive seating solutions for the China market with a focus on serving key Chinese OEMs. The partnership combines Adient's global technology with SCI's local insights to accelerate development and mass production, expand market share, and strengthen Adient's local footprint in China.
Actinium Pharmaceuticals (NYSE: ATNM) will present preclinical data for ATNM-400, a first-in-class Actinium-225 antibody radioconjugate, showing potent anti-tumor activity in triple-negative breast cancer (TNBC) and efficacy in models resistant to tamoxifen and trastuzumab. Data include tumor growth inhibition exceeding 100% at higher doses, elevated target expression in resistant lines, combination activity with standard agents, and a favorable tolerability profile in xenograft models. The program also showed activity in metastatic castrate-resistant prostate cancer and non-small cell lung cancer. The presentation is scheduled for December 11, 2025 at 5:00 PM CT at the San Antonio Breast Cancer Symposium.
Alexander & Baldwin (NYSE: ALEX) amended its unsecured revolving credit facility on November 6, 2025, keeping a $450 million revolver and executing a new $200 million term loan.
The company drew the full $200 million at closing, used proceeds to repay the $191 million outstanding revolver balance, and the term loan matures on November 3, 2030. Interest rate swaps lock the $200 million term loan through maturity, producing an all-in weighted average fixed rate of 4.69%. Management said the moves replenish revolving capacity, lower cost of capital, and extend the weighted average maturity of borrowings by about one year to support strategic growth.
Cars.com (NYSE: CARS) on November 6, 2025 launched Carson™, a multilingual AI search engine that converts conversational queries into targeted vehicle results to simplify filter-driven shopping.
Early performance metrics reported: Carson handles ~15% of web searches, users return 2x more, save 3x more vehicles, generate 2x more leads, and show a ~30% higher conversion from search results to vehicle detail pages. Carson surfaces Cars.com Award winners and understands practical, emotional, lifestyle and specific automotive queries. Planned enhancements include AI summaries, refinement prompts, filter suggestions and personalized comparisons.
Adient (NYSE: ADNT) reported fourth-quarter and full-year fiscal 2025 results on Nov. 5, 2025. Q4 GAAP net income was $18M with diluted EPS of $0.22 and adjusted diluted EPS of $0.52. Q4 adjusted EBITDA was $226M with an adjusted EBITDA margin of 6.1%. For FY25 the company generated $204M of free cash flow and repurchased $125M of shares, equal to ~7% of outstanding shares at the start of the year.
Balance sheet figures at Sept. 30, 2025 included gross debt ~$2.4B, net debt ~$1.4B, and cash $958M. For FY26 management expects improved business performance but warns that lower customer production volumes and increased growth investments will offset gains. An investor conference call occurred Nov. 5, 2025 at 8:30 a.m. ET.
Actinium Pharmaceuticals (NYSE American: ATNM) announced that Sandesh Seth, Chairman and CEO will participate in the Stephens Biotechnology Virtual Fireside Chat on November 4, 2025 from 10:30–11:20 am ET. Company management will be available for one-on-one investor meetings during the virtual event. Investors or advisors seeking to join meetings or request more information should contact their Stephens representative.
Cars Commerce (NYSE: CARS) released its Q3 2025 Industry Insights Report showing a steady U.S. auto market as pricing, production sourcing and incentives influenced activity.
Key points: average new-car price near $49,000 (+0.5% YoY); 2026 models represented one-third of dealer inventory by end of September; U.S.-built vehicles were 56% of dealer inventory in early October; EV wholesale values fell 10.4% QoQ and 17% YoY. The report cites incentives, tariff effects and earlier model-year rollouts as drivers.
